Functional genomic analysis identifies indoxyl sulfate as a major, poorly dialyzable uremic toxin in end-stage renal

Sachin Jhawar1, Prabhjot Singh1, Daniel Torres1

  • 1Department of Medicine New York University Langone Medical Center, New York, NY, United States of America.

Plos One
|March 27, 2015
PubMed
Abstract

Insights

Hemodialysis inadequately removes indoxyl sulfate (IS), a uremic toxin that significantly alters gene expression in renal cells. This suggests IS contributes to kidney disease progression and cardiovascular complications in uremia.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Chronic renal failure leads to kidney scarring and cardiovascular disease despite dialysis.
  • Uremic toxins, such as indoxyl sulfate (IS), are implicated in renal scarring.
  • IS is a small, protein-bound molecule poorly removed by dialysis.

Purpose of the Study:

  • To identify uremic toxins not effectively removed by hemodialysis.
  • To investigate the impact of uremic plasma on gene expression in renal cells.
  • To determine the role of indoxyl sulfate (IS) in uremic toxicity.

Main Methods:

  • Assessed gene expression in human renal cortical cells exposed to pre- and post-dialysis plasma from uremic patients.
  • Compared gene expression patterns with cells exposed to control plasma.
  • Investigated the effects of adding IS to control plasma and probenecid (an OAT inhibitor) to uremic plasma.

Main Results:

  • Uremic plasma significantly dysregulated 1912 genes; 1375 remained dysregulated post-dialysis.
  • Indoxyl sulfate (IS) addition to control plasma mimicked over 80% of uremic plasma's gene expression effects.
  • Probenecid inhibited the gene expression changes induced by uremic plasma.

Conclusions:

  • Hemodialysis is ineffective at clearing certain solutes, like IS, that drive uremic toxicity.
  • Indoxyl sulfate (IS) is identified as a major, poorly dialyzable uremic toxin.
  • IS and other poorly cleared solutes may drive renal scarring and uremic vasculopathy pathogenesis.

Related Concept Videos

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate01:25

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
123
Enhanced Elimination of Poison01:26

Enhanced Elimination of Poison

Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
1.1K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
336
Drug Elimination by Renal Route: Tubular Reabsorption01:22

Drug Elimination by Renal Route: Tubular Reabsorption

During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
5.6K
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
239
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
197